Related Experiment Videos
[Rational therapy of heart failure]
1Medizinische Klinik IV, Universität Erlangen-Nürnberg.
Insights
Angiotensin-converting enzyme (ACE) inhibitors significantly reduce mortality in congestive heart failure patients. These drugs are now standard treatment, helping to prevent disease progression and improve cardiovascular outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) progression remains a significant therapeutic challenge.
- Current standard CHF therapy includes diuretics and glycosides.
Observation:
- Prospective studies demonstrate that angiotensin-converting enzyme (ACE) inhibitors reduce cardiovascular and total mortality in CHF patients.
- ACE inhibitors act as vasodilators and counteract detrimental neuroendocrine system activation.
- The SOLVD-Study prevention trial showed ACE inhibitors can attenuate or halt CHF development in patients with reduced ejection fraction.
Findings:
- ACE inhibitors are established as standard therapy for CHF.
- Treatment with ACE inhibitors leads to a reduction in mortality for CHF patients.
- In patients with reduced ejection fraction post-myocardial infarction, ACE inhibitors are crucial for preventing CHF progression.
Implications:
- Optimal dosing, initiation timing, and duration of ACE inhibitor therapy require further investigation.
- ACE inhibitors are a cornerstone in managing CHF and improving cardiovascular prognosis.
- Future trials will explore potential additional benefits of beta-blockers in specific CHF patient subgroups.
Abstract:
To stop or reverse progression of congestive heart failure is so far an unreached therapeutic goal. Several prospective studies have now clearly shown that treatment with angiotensin-converting enzyme (ACE) inhibitors resulted in a clear reduction of cardiovascular and total mortality in patients with congestive heart failure. As a consequence, ACE-inhibitors are now standard therapy for congestive heart failure in addition to diuretics and glycosides. Of pathophysiologic importance is that ACE-inhibitors are potent vasodilators and counteract the neuroendocrine stimulation of the sympathetic nervous system and the renin-angiotensin-aldosterone system which both contribute to the detrimental outcome in congestive heart failure. New results of the prevention trial of the SOLVD-Study showed that in patients with reduced ejection fraction the development of congestive heart failure could be attenuated or even stopped. The questions remain of what is the optimal dose, when should treatment with ACE-inhibitors be started, and how long should it be maintained. Thus, in patients with reduced ejection fraction after myocardial infarction ACE-inhibitors are today a cornerstone for preventing progressive congestive heart failure and improving cardiovascular prognosis. Whether beta-blockers offer additional benefit in subgroups of patients with congestive heart failure remains to be determined in future trials.